<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621318</url>
  </required_header>
  <id_info>
    <org_study_id>SB16-1001</org_study_id>
    <nct_id>NCT04621318</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Denosumab (SB16, EU Sourced Prolia®, and US Sourced Prolia®) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare PK, PD, safety, tolerability, and immunogenicity profiles of SB16,&#xD;
      EU sourced Prolia, and US sourced Prolia in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">August 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Area under the concentration-time curve from time zero to the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Maximum serum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Apparent volume of distribution during the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCextrap</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Percentage of AUCinf due to extrapolation from Tlast to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC for CTX percent inhibition</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Area under the effect curve from time zero to Day 197 for serum CTX percent inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Experience at least 1 TEAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Experience at least 1 SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADAs</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Incidence of ADAs to denosumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of NAbs</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Incidence of NAbs to denosumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB16 (proposed denosumab biosimilar)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Prolia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU sourced Prolia (denosumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Prolia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US sourced Prolia (denosumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>60 mg, single-dose</description>
    <arm_group_label>EU Prolia</arm_group_label>
    <arm_group_label>SB16</arm_group_label>
    <arm_group_label>US Prolia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male, aged 28-55 years (inclusive) on the day of signing the informed consent.&#xD;
&#xD;
          2. Have a body weight between 60.0-90.0 kg (inclusive) and a BMI between 20.0-29.9 kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          3. Have 12-lead ECG results without clinically significant abnormal findings confirmed by&#xD;
             the Investigator.&#xD;
&#xD;
          4. Have vital sign results without clinically significant abnormal findings confirmed by&#xD;
             the Investigator.&#xD;
&#xD;
          5. Have physical examination results without clinically significant abnormal findings&#xD;
             confirmed by the Investigator.&#xD;
&#xD;
          6. Male subjects who have not had surgical sterilisation must be willing to abstain from&#xD;
             sexual intercourse or willing to use a condom in addition to having their female&#xD;
             partner use another form of contraception, such as an intra-uterine device, oral&#xD;
             contraceptive, injectable progesterone, sub-dermal implant, or tubal ligation unless&#xD;
             their partners are infertile (confirmed with written verifications) during the&#xD;
             treatment period.&#xD;
&#xD;
          7. Willing and able to comply with scheduled visits, treatment plan, clinical laboratory&#xD;
             tests, and other study procedures including lifestyle considerations.&#xD;
&#xD;
          8. Able to provide written informed consent, which must be obtained prior to any study&#xD;
             related procedures being performed.&#xD;
&#xD;
          9. Have competence in speaking, writing, and comprehending the local language(s) where&#xD;
             the study is conducted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history and/or current presence of clinically significant atopic allergy,&#xD;
             hypersensitivity, or allergic reactions (either spontaneous or following drug&#xD;
             administration), also including known or suspected clinically relevant drug&#xD;
             hypersensitivity to denosumab or to any of the excipients.&#xD;
&#xD;
          2. Have a history of and/or current clinically significant gastrointestinal, renal,&#xD;
             hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric&#xD;
             disorder, drug or alcohol abuse, or allergic disease excluding mild asymptomatic&#xD;
             seasonal allergies.&#xD;
&#xD;
          3. Have a history of bone disease or any medical condition that can affect bone&#xD;
             metabolism (including osteoporosis, osteogenesis imperfecta, osteomalacia,&#xD;
             hyperparathyroidism, hyperthyroidism, hypothyroidism, rheumatoid arthritis, psoriatic&#xD;
             arthritis, ankylosing spondylitis, Paget's disease of the bone, and malabsorption&#xD;
             syndrome).&#xD;
&#xD;
          4. Have a history of malignancy (including lymphoma, leukaemia, and skin cancer).&#xD;
&#xD;
          5. Have ONJ or risk factors for ONJ such as invasive dental procedures or active&#xD;
             periodontal disease within 180 days prior to Randomisation.&#xD;
&#xD;
          6. Have bone fractures within 180 days prior to Randomisation.&#xD;
&#xD;
          7. Have a history of serious infection (associated with hospitalisation and/or which&#xD;
             required intravenous antibiotics) within 180 days prior to Randomisation.&#xD;
&#xD;
          8. Have a clinically significant active infection (bacterial, viral, or fungal) including&#xD;
             skin infections within 28 days prior to Randomisation.&#xD;
&#xD;
          9. Have any systemic or local infection, a known risk for developing sepsis.&#xD;
&#xD;
         10. Have known intolerance to calcium or vitamin D supplements.&#xD;
&#xD;
         11. Have previously been exposed to denosumab (Prolia®/Xgeva®) and its biosimilar.&#xD;
&#xD;
         12. Have previously been exposed to a monoclonal antibody or fusion protein within 270&#xD;
             days (other than denosumab) prior to Randomisation and/or there is confirmed evidence&#xD;
             or clinical suspicion of immunogenicity from previous exposure to a monoclonal&#xD;
             antibody or fusion protein.&#xD;
&#xD;
         13. Have previously been exposed to an immunosuppressive agent or biological agent (any&#xD;
             other than a monoclonal antibody or fusion protein) within 120 days prior to&#xD;
             Randomisation.&#xD;
&#xD;
         14. Have received live vaccines(s) within 30 days prior to Randomisation or who will&#xD;
             require live vaccine(s) during the study period.&#xD;
&#xD;
         15. Have a personal or family history of prolonged QT interval syndrome or Torsade de&#xD;
             Pointes, or family history of sudden death.&#xD;
&#xD;
         16. Have any of the following abnormal laboratory test results:&#xD;
&#xD;
               1. Albumin-adjusted serum calcium levels below the LLN or above the ULN.&#xD;
&#xD;
               2. Serum creatinine levels above 1.5 × ULN.&#xD;
&#xD;
               3. Any other laboratory abnormalities assessed as clinically significant by the&#xD;
                  Investigator.&#xD;
&#xD;
         17. Have a positive test result for HBsAg, HCV antibody, or HIV 1or 2.&#xD;
&#xD;
         18. Have a history of immunodeficiency.&#xD;
&#xD;
         19. Have had surgery within 90 days prior to Randomisation, and/or plan to have an&#xD;
             operation (including invasive dental procedure) during the study period.&#xD;
&#xD;
         20. Have a history and/or current presence of an illness (including, but not limited to&#xD;
             respiratory symptoms [e.g., difficulty breathing or persistent cough] or low-grade&#xD;
             fever) within 14 days prior to Randomisation that is classified as clinically&#xD;
             significant by the Investigator.&#xD;
&#xD;
         21. Have smoked more than 10 cigarettes, 2 cigars, or 2 pipes per day within 90 days prior&#xD;
             to Screening.&#xD;
&#xD;
         22. Have regular consumption of alcoholic beverages that exceeds 14 units per week.&#xD;
&#xD;
         23. Have a positive urinary drug screening result or alcohol breath test result at&#xD;
             Screening or Day -1.&#xD;
&#xD;
         24. Have taken any prescription medicine or over-the-counter medicines (except&#xD;
             paracetamol) that might have an effect on the objectives of the study in the opinion&#xD;
             of the Investigator, within 30 days or 10 half-lives of the medication (whichever&#xD;
             period is longer) prior to Randomisation. This includes medications such as, but not&#xD;
             limited to: Bisphosphonates, parathyroid hormone, hormone replacement therapy,&#xD;
             selective estrogen receptor modulators, calcitonin, calcitriol, glucocorticoids,&#xD;
             fluoride, strontium, or anabolic steroids.&#xD;
&#xD;
         25. Have donated &gt; 100 mL blood or plasma within 28 days prior to Randomisation.&#xD;
&#xD;
         26. Have participated in another study with an investigational drug within 60 days prior&#xD;
             to Randomisation or are currently participating in or intending to participate in&#xD;
             another clinical study of an investigational drug before completion of all scheduled&#xD;
             evaluation in this clinical study.&#xD;
&#xD;
         27. Subjects who, in the opinion of the Investigator, are not likely to complete the study&#xD;
             for whatever reason.&#xD;
&#xD;
         28. Subject who is the Investigator or any sub-Investigator, research assistant,&#xD;
             pharmacist, study coordinator, other staff, or relative thereof directly involved in&#xD;
             the conduct of the clinical study.&#xD;
&#xD;
         29. Vulnerable subjects&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakim Charfi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biotrial Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samsung Bioepis</last_name>
    <phone>+82 32 728 0371</phone>
    <email>sbregistry@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biotrial Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biotrial</last_name>
      <phone>+33 2 99 59 91 91</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

